Everything below concerns angiogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molar mass | Approximately 1419.5 g/mol | Calculated from the reported 15-residue sequence |
| Molecular formula | C62H98N16O22 | Based on the same sequence |
| Appearance | White to off-white powder | Typical of a lyophilized preparation |
| Solubility class | Freely soluble in water | Also dissolves in saline solutions |
| Typical storage temperature | Minus 20 degrees Celsius, dry | Refrigeration advised after reconstitution |
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Annular lichen planus Atrophic lichen planus Bullous lichen planus (vesiculobullous lichen planus) Erosive lichen planus Erythema dyschromicum perstans (ashy dermatosis, dermatosis cinecienta) Giant cell lichenoid dermatitis Hepatitis-associated lichen planus Hypertrophic lichen planus (lichen planus verrucosus) Idiopathic eruptive macular pigmentation Inverse lichen planus Keratosis lichenoides chronica (Nékam's disease) Kraurosis vulvae Lichen nitidus Lichen planus actinicus (actinic lichen nitidus, actinic lichen planus, lichen planus atrophicus annularis, lichen planus subtropicus, lichen planus tropicus, lichenoid melanodermatitis, lichenoid melanodermatosis, summertime actinic lichenoid eruption) Lichen planus pemphigoides Lichen planus pigmentosus Lichen planus–lichen sclerosus overlap syndrome Lichen ruber moniliformis Lichen sclerosus (lichen sclerosus et atrophicus) Lichen striatus (Blaschko linear acquired inflammatory skin eruption, linear lichenoid dermatosis) Lichen verrucosus et reticularis Lichenoid trikeratosis Lichenoid dermatitis Lichenoid reaction of graft-versus-host disease Linear lichen planus Mucosal lichen planus Peno-gingival syndrome Ulcerative lichen planus Vulvovaginal gingival syndrome Vulvovaginal lichen planus
=== Ancient history === There have been reports of stupor-like and catatonia-like states in people throughout the history of psychiatry. In ancient Greece, the first physician to document stupor-like or catatonia-like states was Hippocrates, in his Aphorisms. He never defined the syndrome, but seemingly observed these states in people he was treating for melancholia. In ancient China, the first descriptions of people that appear in the Huangdi Neijing (The Yellow Emperor's Inner Canon), the book which forms the basis of Traditional Chinese Medicine. It is thought to have been compiled by many people over the course of centuries during the Warring States Period (475-221 BCE) and the early Han Dynasty (206 BCE-220 CE).
Greenland Prime Minister Jens-Frederik Nielsen called the deal "gratifying" and "for the benefit of us all." On 22 September 2026, during the general debate of the eighty-first session of the United Nations General Assembly, the United States, Denmark, and Greenland signed a security agreement that increases US involvement in Greenland's defence while affirming Danish sovereignty and Greenland's right to self-determination.
Sources: en.wikipedia.org
The territory of Hanover had earlier been a principality within the Holy Roman Empire before being elevated into an electorate in 1708, when Hanover was formed by the union of the dynastic divisions of the Duchy of Brunswick-Lüneburg, excepting the Principality of Brunswick-Wolfenbüttel. After his accession in 1714, George Louis of the House of Hanover ascended the throne of Great Britain as George I, and Hanover was joined in a personal union with Great Britain. In 1803, Hanover was conquered by the French and Prussian armies in the Napoleonic Wars. The Treaties of Tilsit in 1807 joined it to territories from Prussia and created the Kingdom of Westphalia, ruled by Napoleon's youngest brother, Jérôme Bonaparte. French control lasted until October 1813, when the territory was overrun by Russian Cossacks. The Battle of Leipzig, shortly thereafter, spelled the definitive end of the Napoleonic client states, and the electorate was restored to the House of Hanover. The terms of the Congress of Vienna in 1814 not only restored Hanover but also elevated it to an independent kingdom with its Prince-Elector, George III of the United Kingdom, as King of Hanover. The new kingdom was also greatly expanded and became the fourth-largest state in the German Confederation (behind Prussia, Austria and Bavaria) and the second-largest in northern Germany. George III never visited the kingdom during his 60-year reign.
Sulfuryl chloride is an inorganic compound with the formula SO2Cl2. At room temperature, it is a colorless liquid with a pungent odor. Sulfuryl chloride is not found in nature. Sulfuryl chloride is commonly confused with thionyl chloride, SOCl2. The properties of these two sulfur oxychlorides are quite different: sulfuryl chloride is a source of chlorine whereas thionyl chloride is a source of chloride ions. An alternative IUPAC name is sulfuryl dichloride. Sulfur is tetrahedral in SO2Cl2 and the oxidation state of the sulfur atom is +6, as in sulfuric acid.
Cocaine is highly addictive and has poor bioavailability when taken orally. Individuals often engage in repeated use by either insufflating it intranasally or converting it to crack cocaine for vaporization. Cocaine's effects last longest when insufflated (60–90 minutes), but the drug itself has a short biological half-life of about 0.7–1.5 hours. Repeated use raises the risk of developing "cocaine nose," referring to severe nasal tissue damage from intranasal use, as well as "crack lung," a condition involving lung tissue damage caused by inhaling crack cocaine. Cocaine use leads to an increased risk of hemorrhagic and ischemic strokes. Cocaine use also increases the risk of having a heart attack. Cocaine use also promotes the formation of blood clots. This increase in blood clot formation is attributed to cocaine-associated increases in the activity of plasminogen activator inhibitor, and an increase in the number, activation, and aggregation of platelets. Cocaine constricts blood vessels, dilates pupils, and increases body temperature, heart rate, and blood pressure. It can also cause headaches and gastrointestinal complications such as abdominal pain and nausea. Chronic users may lose their appetite and experience severe malnutrition, leading to being underweight. A 2014 study found that increased cocaine use is linked to greater cognitive impairment, particularly in working memory, while reduced or ceased use can lead to partial or full recovery of cognitive function.
Sources: en.wikipedia.org
=== Jamie Henson === Jamie Henson (James Nelson-Joyce) is a constituent of Aurore Adekunle. He suffers from mental illness and repeatedly visits her office demanding to speak with her, claiming that unspecified people are harassing him and defecating on his street. Gus, working for Aurore, takes time to listen to Jamie's concerns, and refers him to a therapist. The two form a friendship that makes Gus realize he enjoys helping everyday people more than working in finance, until Aurore is forced to fire Gus.
== Uses == It is nearly isosteric with methionine, even though it does not contain sulfur. For this reason, norleucine has been used to probe the role of methionine in Amyloid-β peptide (AβP) the central constituent of senile plaques in Alzheimer's disease. A study showed that with the substitution of the methionine at the 35 position with norleucine the neurotoxic effects of the Aβ peptides were completely negated.
In theory, many cancers might be prevented in this way, since an excess of thyroid cancer, presumably due to radioiodine uptake, is the only proven long-term effect after exposure of a population to radioactive fission products from a reactor accident or atomic bomb fallout. Taking large amounts of iodide saturates thyroid receptors and prevents uptake of most radioactive iodine-131 that may be present from fission product exposure (although it does not protect from other radioisotopes, nor from any external radiation). The protective effect of KI lasts approximately 24 hours, so must be dosed daily until a risk of significant exposure to this isotope no longer exists; as it decays relatively rapidly with a half-life of eight days (other iodine isotopes of concern are even shorter-lived), 99.95% of the radioiodine has vanished after three months.
Sources: en.wikipedia.org
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.
It marks the position of the sequence inside the original protein. The label traces back to early work fractionating gastric juice and describing a body protection compound. The figure does not refer to molecular weight or to the count of amino acids.
No. The sequence has no cysteine residues, so disulfide bridges cannot form. That feature makes it easier to handle than many small proteins that depend on multiple cysteines for structure.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.